2025-11-06 - Analysis Report
Okay, here's an analysis of Natera Inc. (NTRA) based on the information you provided.

**1. Performance vs. S&P 500 (VOO)**

*   **Ticker:** NTRA
*   **Company:** Natera Inc.
*   **Description:** Natera Inc. is a diagnostics company focused on cell-free DNA testing.
*   **NTRA Cumulative Return:** 104.25%
*   **VOO Cumulative Return:** 99.78%
*   **Deviation:**
    *   Current: -4.8
    *   Range: Max 174.8, Min -88.5
    *   Relative Deviation: 31.8

**Analysis:** While NTRA has outperformed the S&P 500 overall, the current deviation is negative, indicating recent underperformance. The relative deviation of 31.8 suggests that NTRA is currently closer to its historical minimum deviation compared to VOO, implying it might be undervalued relative to its past performance against the index.

**Alpha/Beta Analysis:**

| Year       | CAGR     | MDD   | Alpha   | Beta   | Cap(B) |
| :----------- | :------- | :------ | :-------- | :----- | :------- |
| 2015-2017  | -10.0%   | 70.1%  | -34.0%  | -0.2  | 1.2    |
| 2016-2018  | 22.0%    | 80.0%  | 6.0%    | 0.1   | 1.9    |
| 2017-2019  | 50.0%    | 80.0%  | 28.0%   | 1.0   | 4.6    |
| 2018-2020  | 186.0%   | 80.5%  | 163.0%  | 1.1   | 13.7   |
| 2019-2021  | 96.0%    | 80.5%  | 49.0%   | 1.6   | 12.8   |
| 2020-2022  | -77.0%   | 80.5%  | -76.0%  | 0.1   | 5.5    |
| 2021-2023  | -194.0%  | 76.6%  | -195.0% | -1.1  | 8.6    |
| 2022-2024  | 8.0%     | 76.6%  | -13.0%  | -1.2  | 21.7   |
| 2023-2025  | 131.0%   | 76.6%  | 67.0%   | 0.1   | 27.2   |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate (CAGR) fluctuates significantly, indicating volatile performance.
*   **MDD:** High Maximum Drawdown (MDD) values point to substantial risk and potential for significant losses.
*   **Alpha:** Alpha is highly variable, suggesting periods of both strong outperformance and underperformance relative to the market. Recent years show negative alpha.
*   **Beta:** Beta values vary. Some periods show a beta around 1, indicating market-like volatility. Other periods exhibit negative betas.

**2. Recent Price Action**

*   **Current Price:** 198.41
*   **Last Market Data:** Price: 198.41, Previous Close: 196.45, Change: 1.0
*   **5-day Moving Average:** 196.32
*   **20-day Moving Average:** 185.91
*   **60-day Moving Average:** 173.19

**Analysis:** The price is above all three moving averages (5, 20, and 60 days), indicating an upward trend in the short, medium, and long term. The slight positive change from the previous close suggests continued positive momentum, and the news may be contributing.

**3. Technical Indicators**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 81.79 (Overbought)
*   **PPO:** 0.39
*   **Hybrid Signal:** "cash\_0%\_Buy 100% of cash (5 shares - Very Safe - MRI:0.90)"
*   **Recent (20-day) Relative Deviation Change:** 0.5 (Short-term Increase)
*   **Expected Return:** -99.2%

**Analysis:**

*   The Market Risk Indicator (MRI) suggests a high level of investment is recommended.
*   The RSI value indicates the stock is currently overbought, which could signal a potential pullback in the short term.
*   The positive change in relative deviation suggests short-term upward momentum.
*   The Hybrid Signal recommends buying, based on the MRI.
*   The significantly negative expected return (-99.2%) indicates that long-term returns are expected to be significantly lower than the S&P 500.

**4. Recent News & Events**

*   **Insider Selling:** A Natera insider sold shares worth $4.59 million (negative signal).
*   **Earnings Report:** Upcoming earnings report (potential volatility).
*   **Positive Coverage:** Inclusion in lists of stocks to watch and expansion of fetal testing tool (positive signals).

**Analysis:** The insider selling is a potentially negative signal, as it may indicate a lack of confidence in the company's future prospects. However, positive news regarding the expansion of fetal testing and inclusion in lists of stocks to watch could offset this negative signal. The upcoming earnings report is a key event that could significantly impact the stock price.

**4-2. Analyst Opinions**

*   **Consensus:** Strong Buy (Mean: 1.50)
*   **Target Price:** Average: $202.50, High: $235.00, Low: $172.00
*   **Recent Rating Changes:** Not specified, but implied to be neutral.

**Analysis:** Analyst consensus is strongly bullish on NTRA, with a consensus rating of Strong Buy. The average target price suggests a moderate upside potential from the current price.

**5. Recent Earnings Analysis**

| 날짜         | EPS   | 매출        |
| :----------- | :---- | :---------- |
| 2025-08-08 | -0.74 | 0.55 B$   |
| 2025-05-09 | -0.50 | 0.50 B$   |
| 2024-11-12 | -0.26 | 0.44 B$   |
| 2024-08-09 | -0.30 | 0.41 B$   |
| 2025-08-08 | -0.30 | 0.41 B$   |

**Analysis:**

*   Natera has consistently reported negative Earnings Per Share (EPS), indicating a lack of profitability.
*   Revenue has generally increased over the past few quarters, suggesting growth in the company's business.
*   The most recent EPS is the worst in the past 5 quarters

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
| :----------- | :-------- | :------------ |
| 2025-06-30 | $0.55B    | 63.41%        |
| 2025-03-31 | $0.50B    | 63.12%        |
| 2024-12-31 | $0.48B    | 62.94%        |
| 2024-09-30 | $0.44B    | 61.79%        |
| 2024-06-30 | $0.41B    | 58.83%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE       |
| :----------- | :-------- | :-------- |
| 2025-06-30 | $1.25B    | -8.10%   |
| 2025-03-31 | $1.24B    | -5.40%   |
| 2024-12-31 | $1.20B    | -4.50%   |
| 2024-09-30 | $0.88B    | -3.60%   |
| 2024-06-30 | $0.84B    | -4.48%   |

**Analysis:**

*   **Revenue and Profitability:** Revenue has been consistently growing over the past few quarters, and the profit margin is relatively high.
*   **Capital and Profitability:** Equity has increased, but the Return on Equity (ROE) is negative, indicating that the company is not generating profits from its equity.

**7. Overall Analysis**

Natera (NTRA) presents a mixed investment picture:

*   **Strengths:** Strong analyst consensus, growing revenue, high profit margins, and a high Market Risk Indicator. Recent price momentum is positive.
*   **Weaknesses:** Negative EPS and ROE, high volatility (MDD), insider selling, an overbought RSI, and significantly negative expected returns compared to the S&P 500.

**Conclusion:**

NTRA appears to be a high-growth, high-risk stock. While analysts are bullish, the company's lack of profitability and high volatility should be considered. The high MRI suggests a higher than average opportunity, but the negative expected return is concerning. Be aware of a potential short-term pullback. Investors should carefully weigh the potential risks and rewards before investing in NTRA. The upcoming earnings report will be a crucial indicator of the company's future performance.
